Coherus BioSciences (NASDAQ:CHRS) Rating Lowered to "Sell" at Wall Street Zen

Wall Street Zen cut shares of Coherus BioSciences (NASDAQ:CHRS - Free Report) from a hold rating to a sell rating in a research report report published on Tuesday morning.

Several other brokerages have also weighed in on CHRS. UBS Group reissued a "neutral" rating and issued a $1.05 price objective (down from $1.50) on shares of Coherus BioSciences in a research report on Thursday, April 24th. HC Wainwright reaffirmed a "buy" rating and set a $7.00 price target on shares of Coherus BioSciences in a research report on Tuesday, April 29th.

Coherus BioSciences Price Performance

Shares of Coherus BioSciences stock traded up $0.00 on Tuesday, hitting $0.78. The company had a trading volume of 904,526 shares, compared to its average volume of 2,715,598. The firm has a market capitalization of $89.86 million, a P/E ratio of -9.69 and a beta of 1.01. Coherus BioSciences has a twelve month low of $0.66 and a twelve month high of $2.43. The stock has a 50-day moving average of $0.92 and a 200-day moving average of $1.13.

Coherus BioSciences (NASDAQ:CHRS - Get Free Report) last released its earnings results on Monday, May 12th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.04). The company had revenue of $7.60 million for the quarter, compared to analyst estimates of $59.79 million. During the same period in the prior year, the business posted ($0.32) earnings per share. Equities analysts predict that Coherus BioSciences will post -1.05 EPS for the current year.

Hedge Funds Weigh In On Coherus BioSciences

A number of hedge funds have recently bought and sold shares of CHRS. Bank of Montreal Can bought a new position in Coherus BioSciences during the fourth quarter worth about $34,000. Intech Investment Management LLC bought a new position in Coherus BioSciences during the fourth quarter worth about $38,000. CWM LLC increased its position in Coherus BioSciences by 96.6% during the first quarter. CWM LLC now owns 49,793 shares of the biotechnology company's stock worth $40,000 after acquiring an additional 24,468 shares during the period. Wealth Enhancement Advisory Services LLC increased its holdings in Coherus BioSciences by 97.3% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 30,847 shares of the biotechnology company's stock valued at $43,000 after buying an additional 15,214 shares during the period. Finally, Cerity Partners LLC increased its holdings in Coherus BioSciences by 84.0% in the 1st quarter. Cerity Partners LLC now owns 54,676 shares of the biotechnology company's stock valued at $44,000 after buying an additional 24,953 shares during the period. 72.82% of the stock is owned by institutional investors.

Coherus BioSciences Company Profile

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.